Source link : https://www.newshealth.biz/health-news/fda-oks-sub-q-vedolizumab-for-crohns-maintenance-therapy/
The US Food and Drug Administration (FDA) has approved the subcutaneous administration of vedolizumab (Entyvio) for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) vedolizumab. The move follows the FDA’s approval last year of subcutaneous vedolizumab for maintenance treatment of adults with moderately to severely […]
Author : News Health
Publish date : 2024-04-19 19:15:59
Copyright for syndicated content belongs to the linked Source.